AS2863619 free base NEW
| Price | $987 | $1360 | $1860 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-08-21 |
Product Details
| Product Name: AS2863619 free base | CAS No.: 2241300-50-3 |
| Supply Ability: 10g | Release date: 2025/08/21 |
Product Introduction
Bioactivity
| Name | AS2863619 free base |
| Description | AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene. |
| In vitro | AS2863619 (1 μM; 22 hours; mouse CD4+ T cells) treatment reduces serine phosphorylation of the PSP motif of STAT5b to ~40% and increases tyrosine phosphorylation in the C-terminal domain to ~160% of control-treated samples. |
| In vivo | AS2863619 (30 mg/kg; p.o.; daily; for 2 weeks; mice) treatment after sensitization with DNFB dampens the degree of the secondary response, with milder infiltration of inflammatory cells into the skin and decreases ratios of IFN-γ+ cells in a skin contact hypersensitivity model, when compared with vehicle-treated control mice. Treg depletion before the elicitation of the secondary response abolishes AS2863619-induced suppression. KLRG1+ Foxp3+ T cells are specifically increased in DNFB sensitized AS2863619-treated mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (752.29 mM), Sonication is recommended. |
| Keywords | STAT5 | GSK3β | GSK3α | CDK8 | CDK19 | AS-2863619 free base | AS2863619 free base | AS-2863619 | AS2863619 | AS 2863619 |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Dinaciclib | Abemaciclib methanesulfonate |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 | |
| $133.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-09 | |
| $0.00/25KG |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY